Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.48 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602528 | 0.88 | KDR (0.63) | KDRACP1CCNE1CDK2CDK5 | |
| SCHEMBL3605827 | 0.75 | KDR (0.43) | KDR | |
| SCHEMBL3603529 | 0.74 | KDR (0.49) | KDR | |
| SCHEMBL7234816 | 0.72 | KDR (0.66) | KDRABL1PDGFRB | |
| SCHEMBL3596194 | 0.71 | KDR (0.51) | KDRNAMPT | |
| SCHEMBL3605343 | 0.71 | KDR (0.48) | KDRPDGFRB | |
| SCHEMBL3602411 | 0.70 | KDR (0.53) | KDRNAMPT | |
| SCHEMBL3595740 | 0.70 | MCHR1 (0.42) | KDR | |
| SCHEMBL3609701 | 0.69 | PIK3CA (0.41) | KDRPDGFRB | |
| SCHEMBL3611617 | 0.69 | CDK4 (0.45) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | claimed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | claimed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | claimed |
| JP-2007511484-A | — | — | 2007-05-10 | — | — | JP | claimed |
| CN-1902186-A | Thiazole and pyrazole derivatives as FLT-3 kinase inhibitors | NOVARTIS AG (CH) | 2007-01-24 | — | — | CN | claimed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | claimed |
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| CN-1902186-B | Thiazole and pyrazole derivatives as FLT-3 kinase inhibitors | NOVARTIS AG | 2010-12-22 | — | — | CN | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| CN-1902186-A | Thiazole and pyrazole derivatives as FLT-3 kinase inhibitors | NOVARTIS AG (CH) | 2007-01-24 | — | — | CN | disclosed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | FLT3, FLT1, FLT4 | KDR 8/4885CAMK2D 1765/4885ACP1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.